Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea

NCT00891371 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00891371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00891371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea
Lead sponsor
Ipsen
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2009
Completion date
August 31, 2013
Enrollment
42 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea